When Congress passed the Inflation Reduction Act in 2022, most headlines focused on lower drug prices for Medicare beneficiaries. Far less attention has been paid to how compressing the product prime earning cycle is reshaping pharmaceutical development and commercialization strategy.

Pharmaceutical leaders need an alternative approach to the blockbuster model of drug development. Narrower labels and targeted indications are now signs of strength and creativity, a rational response to scientific precision and a shorter effective commercial runway. Strategy must adjust accordingly.